Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KHK4083

            Therapeutic Area: Dermatology Product Name: KHK4083

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $1,250.0 million Upfront Cash: $400.0 million

            Deal Type: Collaboration June 01, 2021

            Details:

            KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin’s patented POTELLIGENT® defucosylation technology to enhance its antibody-dependent cellular cytotoxicity (ADCC) activity.